Skip to content
Iron Horse Analytics— home

Blog

340B in Late 2026: What Hospitals Should Watch

· Iron Horse Analytics

On January 1, 2027, 340B hospitals will start paying full price up front for 21 widely used drugs and waiting for rebates. That change, set by HRSA's revised Rebate Model Pilot, drove most of October's 340B news: a new hospital lawsuit, a bipartisan bill to delay the pilot, and a state attorney general pushing back on a drugmaker's data demands.

Hospitals have about nine weeks to prepare.

What changed in October

Five developments matter most, newest first.

DateDevelopmentWhy it matters
Oct. 26Missouri's attorney general ordered Eli Lilly to stop requiring hospitals to hand over claims data before getting 340B prices.States are starting to challenge drugmaker data conditions, not just contract pharmacy limits. The attorney general asked Lilly to end the policy by Nov. 26.
Oct. 9Reps. Bresnahan, Dingell, Mann, and Frankel introduced the 340B Rebate Model Delay Act (H.R. 10770).It would delay the pilot "for two years." Nine more members signed on by Oct. 27, but the bill has not passed.
Oct. 9The AHA, the Maine Hospital Association, and four safety-net hospitals sued in federal court in Maine to stop the pilot.A Maine court blocked the first version of the pilot in December 2025. Plaintiffs asked for a ruling before Jan. 1, and several drugmakers have moved to join the case to defend the pilot.
Oct. 1HRSA approved 10 drugmakers for the pilot: AbbVie, Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, GSK, Merck, Pfizer, and Teva.The 21 drugs include Eliquis, Jardiance, Farxiga, Januvia, Enbrel, Imbruvica, and Xtandi. They will be the only drugs sold through rebates in 2027.
OngoingDrugmakers kept fighting state contract pharmacy laws in court, including Hawaii's.Your contract pharmacy savings may depend on which state you are in and how its case turns out.

How the pilot works. Hospitals buy the 21 drugs through their usual 340B wholesaler account at full wholesale price. They then submit claims data within 45 days through Beacon, a platform run for the drugmakers (Medical Daily). Drugmakers must pay or deny each rebate "within 10 calendar days" of a complete claim, according to HRSA's notice.

HRSA says these drugs make up "less than 5.5%" of 340B sales, and that "upfront discounts remain in place for every other drug" (Becker's).

What it means for hospitals

The pilot touches a small share of drugs, but it shifts cash, paperwork, and risk onto hospitals.

Areas of concern

  • Cash flow. Hospitals front the full price and wait for rebates. A Maine Hospital Association survey found a gap of 11 days to a month, while wholesalers expect payment in 7 to 15 days. One plaintiff, Eastern Maine Medical Center, expects to advance about $14 million a year (HFMA).
  • Paperwork cost. HRSA puts the average reporting cost at about $34,320 a year for each participating hospital or clinic. The AHA estimates the pilot could cost hospitals more than $1 billion a year in total; the government estimate is $537 million.
  • Denied rebates. Drugmakers can deny a rebate for an incomplete claim. Becker's notes they "cannot deny a rebate over concerns about eligibility, diversion or duplicate discounts," but hospitals must still catch and dispute every denial.
  • Thin margins at risk. For Unity Medical Center in North Dakota, 340B savings equal 73% of its projected 2026 operating margin. A hospital that depends this heavily on 340B has little room to wait for rebates.
  • The pilot could grow. If it survives in court, hospitals worry rebates could spread to much more of the program (Becker's).

Opportunities

  • Your exposure is measurable. Only 21 drugs are in the pilot. Pull last year's 340B purchases of those drugs to estimate, in dollars, how much cash you will need to advance.
  • Clean claims data pays twice. Complete, accurate claims speed up rebates and help defend against duplicate-discount disputes. CMS has also proposed making 340B Part D claims data submission mandatory on Jan. 1, 2027 (Mintz).
  • States are stepping in. Missouri's action against Lilly shows that at least one attorney general will act. Documenting every denied discount gives your state, your association, and your lawyers something to act on.
  • Advocacy has momentum. The delay bill has support from both parties. Hospitals that bring their own numbers give representatives concrete reasons to back it.

Warnings before January 1

  1. Don't count on a rescue. A court order or the delay bill could stop the pilot, but neither has happened. Plan as if rebates start on Jan. 1.
  2. Buy pilot drugs through the right account. Mintz warns: "Providers should not buy pilot drugs through any other account (WAC-only or GPO) if they intend to seek a rebate." Check automatic reorders in every pharmacy and clinic.
  3. Watch the 45-day clock. A claim filed late or incomplete can mean a lost rebate. Assign someone to track denials from day one.
  4. Read every new drugmaker data request closely. Before sharing claims data outside the pilot, check what your state allows and talk to counsel.
  5. Recheck your own eligibility. Hospitals must recertify 340B eligibility every year, and a small drop in your DSH percentage can push you below the line. Know where you stand before a drugmaker or auditor asks.

This post is general information, not legal advice. Rules and court rulings are changing quickly, so confirm details with HRSA and your counsel.

How Iron Horse can help

Iron Horse Analytics tracks the 340B status of more than 5,400 hospitals, refreshed every week, and shows where each one stands against its eligibility test. We can help you size your exposure to the pilot, check your eligibility margin, and prepare the numbers for your board or your representatives.

Write to us at info@ironhorseanalytics.com or request a free trial to see where your hospitals stand.

Sources

All posts